Zylox-Tonbridge and GL Capital Agree to HK$1.48 Billion Stake in LifeTech, Plan Merger Push

Two Hong Kong-listed Chinese medical device makers are lining up to combine. On Friday, Nov. 6, Zylox-Tonbridge Medical Technology (HKEX: 2190) and private equity firm GL Capital announced a conditional deal to put about HK$1.482 billion into LifeTech Scientific (HKEX: 1302).

The stated goal is an integrated vascular and structural heart intervention platform in China. Zylox-Tonbridge says it also intends to pursue a merger with LifeTech.

How the deal is built

The money flows through a joint vehicle, GL Lighthouse Two Investment Limited. It would subscribe for 926,342,480 new LifeTech shares at HK$1.60 each. That equals 20.0% of LifeTech's existing issued shares and about 16.7% of the enlarged total, assuming no other changes to share capital.

Once the deal is fully completed, Lighthouse Two becomes LifeTech's largest single shareholder.

Zylox-Tonbridge would pay about HK$889.3 million from internal resources for 60% of Lighthouse Two. GL Lighthouse One holds the other 40%. Per the transaction filing, that gives Zylox-Tonbridge the vehicle's voting position in LifeTech but an effective economic interest of only about 10.0%.

A second deal runs the other direction

A linked agreement sends GL Capital's money into Zylox-Tonbridge itself. Through GL Lighthouse Three, GL Capital would subscribe for 39.8 million new Zylox-Tonbridge H shares at HK$22 each, about 10.8% of the enlarged share capital.

That price is a 13.5% premium to Zylox-Tonbridge's Nov. 6 closing price of HK$19.39, and a 15.4% premium to its five-day average close. The company describes the premium as a sign of GL Capital's confidence in its long-term prospects.

Gross proceeds would be about HK$875.6 million, or HK$863.6 million after expenses. The money is earmarked for potential investments or acquisitions, including a possible further move on LifeTech. Directors estimate it will be fully used by the end of 2028, and say that timetable could change with business and market conditions.

Zylox-Tonbridge and GL Capital may also buy additional LifeTech shares beyond this subscription.

What each company brings

Zylox-Tonbridge makes neurovascular and peripheral vascular products. LifeTech covers aortic and structural heart disease, including the LAmbre and LAxible left atrial appendage occluders and three generations of congenital heart defect occluders. Together they would span four therapeutic areas.

International reach is a central part of the pitch. LifeTech has seven subsidiaries outside mainland China and a sales network covering nearly 120 countries and regions. Its 2025 revenue outside the mainland was nearly RMB 400 million, up about 14.4% and nearly 30% of its total.

Zylox-Tonbridge reports first-half 2026 international revenue growth of 349.3%, commercialization in 70 countries and regions outside the mainland, and a distribution network covering more than 135. It has already bought and integrated Germany-based optimed to build out its European operations. Deal-tracking platform Dealroom puts Zylox-Tonbridge's first-half 2026 revenue at US$86.9 million, up 31.1%.

Part of a consolidation wave

The deal lands in a sector that is already consolidating. According to Dealroom, LifeTech agreed in May to buy 96.46% of Starway Medical for about US$257.1 million. Dealroom also notes LifeTech's shares are down 13.1% over the past year.

Chinese cardiovascular device makers are racing to assemble broader "pan-vascular" portfolios under single roofs, Dealroom says. A completed Zylox-Tonbridge and LifeTech merger would put neurovascular, peripheral, aortic and structural heart businesses in one company.

What is still open

Nothing here has closed. The share subscriptions are conditional agreements, and the filing describes the investment as an initial step.

The merger is only an intention. Neither company has announced an exchange ratio, a price, a timeline or a formal offer. Execution, regulatory review and integration are the main uncertainties.

The next concrete marker is completion of the two share subscriptions. Whether Zylox-Tonbridge follows with a formal merger proposal for LifeTech is undecided, and the use of the Zylox-Tonbridge proceeds is slated to run through the end of 2028.